Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
ntravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC)
Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer
Lung cancer (LC) continues to be the leading cause of cancer-related deaths in both men and women worldwide.
Dectin-1 Signaling Update: New Perspectives for Trained Immunity
The C-type lectin receptor Dectin-1 was originally described as the β-glucan receptor expressed in myeloid cells, with crucial functions in antifungal responses.
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells
Conventional type 1 dendritic cells (cDC1s) are central to antitumor immunity and their presence in the tumor microenvironment associates with improved outcomes in patients with cancer.
Myeloid cells in sensing of tissue damage
Myeloid cells are components of the innate immune system that represent the first line of defense.
Sensing Tissue Damage by Myeloid C-Type Lectin Receptors
After both sterile and infectious insults, damage is inflicted on tissues leading to accidental or programmed cell death.
Clec2d Joins the Cell Death Sensor Ranks
Sensing tissue damage is an ancient function of immune cells that is central to the regulation of inflammation, tissue repair, and immunity.
A Proposal for Nomenclature in Myeloid C-Type Lectin Receptors
Myeloid C-type lectin receptors (CLRs) comprise a family of receptors expressed by immune myeloid cells that share homologous C-type lectin domains.
cDC1s: New Orchestrators of Tissue Innate Immunity
Type-I conventional dendritic cells (cDC1s) are key in inducing adaptive immunity.
Targeting SHIP-1 in Myeloid Cells Enhances Trained Immunity and Boosts Response to Infection
β-Glucan-induced trained immunity in myeloid cells leads to long-term protection against secondary infections.